Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05913232 · ClinicalTrials.gov registry record · Phase 2
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle Primary, sponsored by D. Western Therapeutics Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 9
- Study locations
NCT05913232: Completed Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle Primary, sponsored by D. Western Therapeutics Institute.
NCT05913232 is a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle Primary that has completed, run by D. Western Therapeutics Institute. The registered enrollment target is 201 participants, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (27% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05913232, a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle Primary, has completed, sponsored by D. Western Therapeutics Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 9
- Study locations
Study Summary
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
Primary Outcome
Mean change in intraocular pressure from baseline on Day 28 compared to timolol
Conditions Studied
Interventions
- DRUG Timolol 0.5%
- DRUG H-1337 0.6%
- DRUG H-1337 1.0%
- DRUG H-1337 Placebo
Study Locations (9)
Florida
- Central Florida Eye Associates - Lakeland
- Shettle Eye Research, Inc. - Largo
Georgia
- Dixon Eye Care - Albany
- Coastal Research Associates, LLC - Roswell
California
- Global Research Management - Glendale
Colorado
- Skyline Vision Clinic and Laser Center - Colorado Springs
New York
- Rochester Ophthalmological Group, PC - Rochester
Tennessee
- University Eye Specialists - Maryville
Virginia
- Vistar Eye Center - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-08-28 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 2 |
What the finished NCT05913232 record still lists
NCT05913232 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Timolol 0.5% is the first listed.
NCT05913232 lists 9 locations in 7 states (Florida, Georgia, California).
Frequently Asked Questions
What is clinical trial NCT05913232 about?
NCT05913232 is a clinical study titled "Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension". The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
What is the current status of trial NCT05913232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2023-08-28. Estimated completion is 2024-08-29.
What conditions does trial NCT05913232 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle Primary.
What interventions are being tested in trial NCT05913232?
The interventions under investigation include: Timolol 0.5% (DRUG), H-1337 0.6% (DRUG), H-1337 1.0% (DRUG), H-1337 Placebo (DRUG).
Who is sponsoring clinical trial NCT05913232?
This trial is sponsored by D. Western Therapeutics Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05913232 being conducted?
This trial has 9 study locations across California, Colorado, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05913232's enrollment target sits among peer trials
201 22nd of 54 higher than 32 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI